3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Sarcoma
1
Lymphoid
1
Genitourinary
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Interventions
Magnetic Resonance Spectroscopy
8
X-Rays
7
Specimen Handling
7
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Biopsy
5
ulixertinib
3
trametinib
3
palbociclib
3
larotrectinib
3
erdafitinib
3
Temozolomide
3
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
ensartinib
2
dabrafenib
2
Vemurafenib
2
Topotecan
2
Paclitaxel
2
Nivolumab
2
Lomustine
2
LY3023414
2
Gemcitabine
2
Filgrastim
2
varlilumab
1
trastuzumab biosimilar HLX02
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
CLR1404
×
Lymphoid
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled